[Remote] Associate Director, Oncology Patient Support Operations at Corcept Therapeutics

Remote

Corcept Therapeutics Logo
Not SpecifiedCompensation
Expert & Leadership (9+ years)Experience Level
Full TimeJob Type
UnknownVisa
Pharmaceuticals, Biotechnology, HealthcareIndustries

Requirements

Candidates should have a background in Oncology patient support services with hands-on experience in managing operational workflows, supporting program development, and working closely with vendors and internal teams. A patient-centric mindset and the ability to act as an advocate for patients are essential. Experience in financial stewardship, including budget planning, forecasting, and management of vendor contracts, is also required.

Responsibilities

The Associate Director will co-lead the design, development, and execution of patient services strategies for the commercial launch and lifecycle management of Oncology therapies, defining long-term program vision. They will provide strategic oversight of core patient support programs, including hub services, free trial programs, co-pay assistance, and patient assistance programs. Responsibilities also include building and leading relationships with external vendor partners, establishing governance frameworks, and implementing continuous quality improvement initiatives. The role involves establishing KPIs and dashboards for performance monitoring, presenting strategic analyses to senior leadership, and acting as an advocate for the patient. Additionally, the Associate Director will co-lead process enhancements, serve as the enterprise subject-matter expert for patient services, ensure compliance with regulatory and legal requirements, and co-lead patient services budget planning and management.

Skills

Patient Support Programs
Oncology
Program Development
Operational Workflows
Vendor Management
Cross-functional Collaboration
Communication

Corcept Therapeutics

Develops cortisol modulators for medical conditions

About Corcept Therapeutics

Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing various health issues. Their main product, Korlym, is used to treat Cushing's syndrome, a condition caused by too much cortisol. Korlym was approved by the FDA in 2012 and is the first medication specifically for this disorder. Corcept stands out from competitors by having a strong emphasis on research and development, having discovered over 1,000 unique cortisol modulators. The company aims to expand its range of treatments while also providing educational resources to healthcare professionals and patients to improve understanding and care for cortisol-related conditions.

Menlo Park, CaliforniaHeadquarters
1998Year Founded
$39.7MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
201-500Employees

Benefits

Remote Work Options
Flexible Work Hours

Risks

Teva's antitrust lawsuit could lead to legal expenses and market share loss.
Heavy reliance on Korlym makes Corcept vulnerable to market fluctuations.
Recent investments may pressure Corcept for short-term financial performance, impacting R&D.

Differentiation

Corcept specializes in cortisol modulation, a niche with few direct competitors.
Korlym is the first FDA-approved treatment for Cushing's syndrome, a significant market advantage.
Corcept's extensive R&D has led to the discovery of over 1,000 selective cortisol modulators.

Upsides

Increased interest in cortisol therapies for mental health boosts Corcept's R&D prospects.
Advancements in drug delivery systems could enhance Corcept's product efficacy.
The FDA's fast-track designation supports Corcept's innovative cortisol-related treatments.

Land your dream remote job 3x faster with AI